Auszug der Leitlinieninhalte 2014 bezüglich einer Glukokortikoidtherapie

• Literatur

• 1 Van Staa TP. et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15 (06) 993-1000. [Evidenzgrad 2b Oxford].
• 2 van Staa TP. et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39 (12) 1383-1389. [Evidenzgrad 2b Oxford].
• 3 van Staa TP. et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001; 51 (06) 601-607. [Evidenzgrad 3b Oxford].
• 4 van Staa TP, Leufkens HGC, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13 (10) 777-787. [Evidenzgrad 1a Oxford].
• 5 Sugiyama T. et al. Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid-treated male patients. Intern Med 2011; 50 (08) 817-824. [Evidenzgrad 3b Oxford].
• 6 van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006; 79 (03) 129-137. [Evidenzgrad 2a Oxford].
• 7 Ghazi M. et al. Prevalence of vertebral fractures in patients with rheumatoid arthritis: revisiting the role of glucocorticoids. Osteoporos Int 2012; 23 (02) 581-587. [Evidenzgrad 3b Oxford].
• 8 Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011; 66 (08) 699-708. [Evidenzgrad 1a Oxford].
• 9 Yang IA. et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; (07) CD002991. [Evidenzgrad 1a Oxford].
• 10 Drummond MB. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300 (20) 2407-2416. [Evidenzgrad 1a Oxford].
• 11 Majumdar SR. et al. Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int 2013; 24 (09) 2493-2498. [Evidenzgrad 2b Oxford].
• 12 Vestergaard P. et al. Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 2002; 146 (01) 51-56. [Evidenzgrad 3 Oxford].
• 13 Chiodini I. et al. Skeletal involvement in adult patients with endogenous hypercortisolism. J Endocrinol Invest 2008; 31 (03) 267-276. [Evidenzgrad 5 Oxford].
• 14 Dekkers OM. et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013; 98 (06) 2277-2284. [Evidenzgrad 2b Oxford].
• 15 Tauchmanova L. et al. Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 2006; 91 (05) 1779-1784. [Evidenzgrad 3b Oxford].
• 16 Tauchmanova L. et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur J Endocrinol 2007; 157 (03) 359-366. [Evidenzgrad 3b Oxford].
• 17 Chiodini I. et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004; 89 (05) 2237-2241. [Evidenzgrad 3b Oxford].
• 18 Chiodini I. et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J Clin Endocrinol Metab 2009; 94 (09) 3207-3214. [Evidenzgrad 3b Oxford].
• 19 Morelli V. et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. J Bone Miner Res 2011; 26 (08) 1816-1821. [Evidenzgrad 2b Oxford].
• 20 Adachi JD. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44 (01) 202-211. [Evidenzgrad SIGN 1+].
• 21 Adachi JD. et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000; 27 (10) 2424-2431. [Evidenzgrad SIGN 1-].
• 22 Wallach S. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67 (04) 277-285. [Evidenzgrad SIGN 1-].
• 23 Reid DM. et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69 (04) 242-247. [Evidenzgrad SIGN 1-].
• 24 Saag KG. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357 (20) 2028-2039. [Evidenzgrad SIGN 1+].
• 25 Saag KG. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60 (11) 3346-3355. [Evidenzgrad SIGN 1+].
• 26 Gluer CC. et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the Euro-GIOPs trial. J Bone Miner Res 2013; 28 (06) 1355-1368. [Evidenzgrad SIGN 1+].